EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in the Treatment of Autosomal Dominant Polycystic Kidney Disease and Novel Therapeutic Targets

Wenzheng Zhang, Tianze Sun iD, Xin Wang iD, Tao Jiang iD

Current Issues in Molecular Biology · 30.04.2026 · 48 (5) · 468

DOI: 10.3390/cimb48050468 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 30.04.2026. Verfasst von Wenzheng Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences, Beihua University, Jilin 132013, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Province Science and Technology Department, Jilin Provincial Department of science and technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autosomal dominant polycystic kidney disease (ADPKD), with a prevalence of approximately 1 in 1000, is the most common inherited cause of end-stage renal disease (ESRD). It is primarily caused by mutations in the PKD1 or PKD2 genes. Multiple studies have demonstrated that deficiency of polycystin proteins, dysregulation of signaling pathways, and activation of inflammatory factors contribute to the progression of ADPKD. The cAMP-targeting drug tolvaptan is currently the only approved therapy for ADPKD; however, its side effects and high cost have limited its widespread use. Meanwhile, mTOR inhibitors, AMPK-targeting agents, anti-inflammatory agents, and dietary interventions have shown promising results in treating ADPKD. Furthermore, the emergence of novel targets such as Notch3 and AURKA offers new directions for ADPKD therapy. This article aims to review the pathogenesis of ADPKD and current treatment advances, while exploring potential new targets for future research, hoping to provide a scientific theoretical foundation for disease management.

Schlagwörter

Stichwörter der Autor:innen

ADPKDcAMPmTOR inhibitorsnovel targetstolvaptantreatment

Autor:innen und Institutionen

  • School of Basic Medical Sciences, Beihua University, Jilin 132013, China.

ORCID-Profile: Tianze Sun, Xin Wang, Tao Jiang

Förderung

  • Jilin Province Science and Technology Department
  • Jilin Provincial Department of science and technology

Zitieren

APA

Zhang, W., Sun, T., Wang, X., & Jiang, T. (2026). Advances in the Treatment of Autosomal Dominant Polycystic Kidney Disease and Novel Therapeutic Targets. Current Issues in Molecular Biology, 48(5), 468. https://doi.org/10.3390/cimb48050468

Vancouver

Zhang W, Sun T, Wang X, Jiang T. Advances in the Treatment of Autosomal Dominant Polycystic Kidney Disease and Novel Therapeutic Targets. Current Issues in Molecular Biology. 2026;48(5):468. doi:10.3390/cimb48050468

BibTeX
@article{Zhang2026,
  author = {Zhang, Wenzheng and Sun, Tianze and Wang, Xin and Jiang, Tao},
  title = {Advances in the Treatment of Autosomal Dominant Polycystic Kidney Disease and Novel Therapeutic Targets},
  journal = {Current Issues in Molecular Biology},
  year = {2026},
  volume = {48},
  number = {5},
  pages = {468},
  doi = {10.3390/cimb48050468}
}
Kostenlos starten →